{
    "ucits": true,
    "type": "ETP",
    "leverage": true,
    "derivatives": true,
    "swaps": true,
    "inverse": true,
    "replication_method": "synthetic",
    "complex_factors": [
        "Leverage",
        "Synthetic replication via swaps",
        "Embedded derivatives",
        "Counterparty risk",
        "Collateralized swap exposure",
        "Daily leverage reset and compounding effects",
        "High risk rating (7/7)",
        "Opaque payoff structure"
    ],
    "classification": "complex",
    "supporting_data": "The GraniteShares 3x Short AstraZeneca Daily ETP is an exchange traded product that seeks to replicate -3 times the daily performance of AstraZeneca PLC through a swap with Natixis, which is collateralized. This product uses synthetic replication via total return swaps, embedding derivatives integral to its investment objective. It employs 3x leverage with daily reset, causing compounding effects that make returns over periods longer than one day deviate significantly from the underlying asset's performance. The product carries high counterparty and collateral risk, which are difficult for retail investors to understand. It is explicitly stated as not simple and difficult to understand, with a highest risk class of 7/7. The product is not capital protected and may result in total loss of investment. These features align with MiFID II criteria for complex instruments, including the use of derivatives central to the strategy, leverage beyond UCITS limits, synthetic replication, and complexity in payoff and risk profile. Therefore, it must be classified as complex under MiFID II rules and requires an appropriateness assessment before sale to retail investors."
}